Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Oct 19, 2023 11:28pm
143 Views
Post# 35692348

RE:Lets try & stay on topic, this is a great and detailed repor

RE:Lets try & stay on topic, this is a great and detailed reporCanadafan invests his hard earned savings in a stock and then honestly believes that the SP is not significant. One can only imagine the amount he has lost on his investment in ONC (and other companies) with this mindset over the past couple of decades.

Not once in the past 24 years has an analyst (or Canadafan) correctly predicted an uptick in ONC's shareprice.

ONC's shares are in the toilet right now for many reasons, some of the top that come to mind are:

1.  Pelareorep (aka Reolysin) has failed every phase 2 trial ever conducted, regardless of the combination therapy employed.

2.  Pelareorep has not advanced to a Phase 3 BC trial now FIVE YEARS after concluding its heralded P2 and announcing itself as a "Breast Cancer Company"

3.  120 days and counting since MC's self-imposed 90 day period for formalizing PanCAN.

4.  ATM ATM ATM ATM ATM (gotta pay those salaries!!)

5.  MATT COFFEY is the CEO

And...

Can't fix #1, unless they change the product name again and sweep everything under the carpet.

Can't fix #2... the BC file is never going forward.

Can't fix #3... MC has zero credibility, always overpromises and underdelivers.

Can't fix #4... ONC is as addicted to their ATM as any penny stock biotech.

Can Fix #5...  Step up B.O.D!

Very sad to think that after 25 years it is one small Panc trial with about a dozen patients enrolled that is keeping this whole stinking ship afloat.

Oh, but do keep on posting Canadafan. Always entertaining, thanks.


<< Previous
Bullboard Posts
Next >>